Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression

Current Opinion in Investigational Drugs

Volumn 8, Issue 7, 2007, Pages 563-569

  Nihalani, N D ^a   Schwartz, T L ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA (1,3 BENZODIOXOL 5 YL) 17BETA HYDROXY 17ALPHA (1 PROPYNYL)ESTRA 4,9 DIEN 3 ONE; ALPHA INTERFERON; C 1073; CORTICOSTERONE; GLUCOCORTICOID ANTAGONIST; HYDROCORTISONE; MEMANTINE; MIFEPRISTONE; OLANZAPINE; ORG 34850; PLACEBO; RU 009; RU 044; RU 39009; RU 43044; UNCLASSIFIED DRUG;

ACUTE STRESS DISORDER; ALZHEIMER DISEASE; BIPOLAR DISORDER; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUSHING DISEASE; DELIRIUM; DEPRESSIVE PSYCHOSIS; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SYNTHESIS; HAMILTON SCALE; HUMAN; HYDROCORTISONE RELEASE; MAJOR DEPRESSION; MIGRAINE; NAUSEA; NONHUMAN; OBESITY; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; REVIEW; SEDATION; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; THERAPY EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT CHANGE;

ANIMALS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DEPRESSIVE DISORDER, MAJOR; GLUCOCORTICOIDS; HORMONE ANTAGONISTS; HUMANS; MIFEPRISTONE; MOLECULAR STRUCTURE; PSYCHOTIC DISORDERS;

EID: 34347341612     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. 65762 The new steroid analog RU 486 inhibits glucocorticoid action in man. Bertagna X, Bertagna C, Luton JP, Husson JM, Girard F J CLIN ENDOCRINOL METAB 1984 59 1 25-28
2. 65764 RU 486: A steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day. Gaillard RC, Riondel A, Muller AF, Herrmann W, Baulieu EE PROC NATL ACAD SCI USA 1984 81 12 3879-3882
3. 68194 Studies on the glucocorticoid-receptor blocking action of RU 38486 in cultured ACTH-secreting human pituitary tumour cells and normal rat pituitary cells. Lamberts SW, Bons EG, Uitterlinden P ACTA ENDOCRINOL 1985 109 1 64-69
4. 78281 Pharmacokinetics and metabolism of RU 486. Lahteenmaki P, Heikinheimo O, Croxatto H, Spitz I, Shoupe D, Birgerson L, Luukkainen T J STEROID BIOCHEM 1987 27 4-6 859-863
5. 94640 Procedures on handling mifepristone (RU 486) in France. Sarrut B, Doreau C HOSP PHARM 1990 25 7 655-658
6. 151352 Dose-response relationship of RU 486. Heikinheimo O, Kekkonen R ANN MED 1993 25 1 71-76
7. 350762 Aventis, new world leader in life sciences, launched today; Rhone-Poulenc shareholders overwhelmingly approve final steps of merger with Hoechst; Supervisory Board members appointed; full listing on world stock exchanges on December 20. Rhone Poulenc SA PRESS RELEASE 1999 December 15
8. 474506 An open label trial of C-1073 (mifepristone) for psychotic major depression. Belanoff JK, Rothschild AJ, Cassidy F, DeBattita C, Baulieu E-E, Schold C, Schatzberg AF BIOL PSYCHIATRY 2002 52 5 386-392
9. 474521 Rapid reversal of psychotic depression using mifepristone. Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF J CLIN PSYCHOPHARMACOL 2001 21 5 516-521
10. 474522 Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D J CLIN ENDOCRINOL METAB 2001 86 8 3568-3573
11. 489839 Depression & anxiety - SMi conference, shining light into dark corners, London, UK. Durrance A IDDB MEETING REPORT 2003 May 12-13
12. 523015 Corcept Therapeutics files registration statement for initial public offering. Corcept Therapeutics Inc PRESS RELEASE 2004 February 11
13. 541084 Psychiatric Disorders - SMI conference, London, UK. Kibble A IDDB MEETING REPORT 2004 May 24-25
14. 548359 Drug development pipeline: Org-34850. NV Organon COMPANY COMMUNICATION 2004 June 14
15. 556808 FDA and Corcept agree on Corlux trial design for psychotic depression. Corcept Therapeutics Inc PRESS RELEASE 2004 August 30
16. 588236 Corcept Therapeutics announces fourth quarter 2004 results Corcept Therapeutics Inc PRESS RELEASE 2005 March 03
17. 599518 Corcept Therapeutics initiates third phase III trial of CORLUX® Corcept Therapeutics Inc PRESS RELEASE 2005 May 04
18. 625154 Corcept closes Corlux AD study enrollment due to lack of suitable patients. Corcept Therapeutics Inc PRESS RELEASE 2005 September 26
19. 638860 In vivo and in vitro characterisation of the glucocorticoid receptor antagonist 34517. Thomson F, Broekkamp C, Craighead M, Eason S, Hillier A, Peeters B, Speake M, Watson L J AFFECT DISORD 2004 78 Suppl 1 S138
20. 686090 Corcept's Corlux fails in phase III psychotic depression trial. Corcept Therapeutics Inc PRESS RELEASE 2006 August 25
21. 692362 The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats. Beebe KL, Block T, Debattista C, Blasey C, Belanoff JK BEHAV BRAIN RES 2006 171 2 225-229
22. 692363 Mifepristone for the prevention of olanzapine-induced weight gain in rats. Beebe KL, Block T, DeBattista C, Blasey C, Schatzberg AF NEUROPSYCHOPHARMACOLOGY 2005 30 Suppl 1 S130
23. 711137 Corcept's Corlux fails second phase III psychosis study. Corcept Therapeutics Inc PRESS RELEASE 2006 September 29
24. 776086 Corcept's Corlux fails third phase III psychosis study. Corcept Therapeutics Inc PRESS RELEASE 2007 March 19
25. 779246 Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. DeBattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C, Carpenter LL, Alva G BIOL PSYCHIATRY 2006 60 12 1343-1349
26. 779249 Clinical and biological effects of mifepristone treatment for psychotic depression. Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF NEUROPSYCHOPHARMACOLOGY 2006 31 3 628-636
27. 779251 An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression. Simpson GM, El Sheshai A, Loza N, Kingsbury SJ, Fayek M, Rady A, Fawzy W J CLIN PSYCHIATRY 2005 66 12 598-602
28. 789815 Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN NEUROPSYCHOPHARMACOLOGY 2004 29 8 1538-1545
29. 789888 NCT00208156: A United States extension study of Corlux for recurrent psychotic symptoms in psychotic major depression. WWW.CLINICALTRIALS.GOV 2007 February 22
30. 789892 NCT00128505: An international extension study of Corlux for recurrent psychotic symptoms in psychotic major depression. WWW.CLINICALTRIALS.GOV 2007 February 22
31. 789893 NCT00130676: A United States study of Corlux for psychotic symptoms in psychotic major depression. WWW.CLINICALTRIALS.GOV 2006 September 18
32. 789897 NCT00146523: An international study of the safety and tolerability of Corlux for psychotic symptoms in psychotic major depression. WWW.CLINICALTRIALS.GOV 2007 February 22
33. 789898 NCT00128479: A United States study of the safety and tolerability of Corlux for psychotic symptoms in psychotic major depression. WWW.CLINICALTRIALS.GOV 2007 February 22
34. 789900 NCT00455442: A two-week study of the efficacy and safety of mifepristone in the prevention of olanzapine-induced weight gain. WWW.CLINICALTRIALS.GOV 2007 March 30
35. 789903 NCT00105105: Mifepristone as adjunctive therapy in Alzheimer's disease. WWW.CLINICALTRIALS.GOV 2005 September 28
36. 790367 Form 10-K 2006 Corcept Therapeutics Inc. Corcept Therapeutics Inc FORM 10-K 2007 April 02
37. 791900 Detecting psychotic major depression using psychiatric rating scales. Keller J, Gomez RG, Kenna HA, Poesner J, DeBattista C, Flores B, Schatzberg AF J PSYCHIATR RES 2006 40 1 22-29
38. 791903 Pharmacotherapy for psychotic depression. Howland RH J PSYCHOSOC NURS MENT HEALTH SERV 2006 44 12 13-17
39. 791917 DST studies in psychotic depression: A meta-analysis. Nelson JC, Davis JM AM J PSYCHIATRY 1997 154 11 1497-1503
40. 791928 Pathophysiology of hypercortisolism in depression. Carroll BJ, Cassidy F, Naftolowitz D, Tatham NE, Wilson WH, Iranmanesh A, Liu PY, Veldhuis JD ACTA PSYCHIATR SCAND SUPPL 2007 433 90-103
41. 791931 Cortisol hypersecretion in unipolar major depression with melancholic and psychotic features: Dopaminergic, noradrenergic and thyroid correlates. Sahoo M, Subho C PSYCHONEUROENDOCRINOLOGY 2007 32 2 210-212
42. 791934 Therapeutic armamentarium. In: BIOLOGICAL PSYCHIATRY D'haenen HAH, Den Boer JA, Willner P, den Boer JS (Eds), John Wiley & Sons, Chichester, UK. 2002 861-875
43. 791989 Brief treatment with the glucocorticoid receptor antagonist mifepristone normalises the corticosterone-induced reduction of adult hippocampal neurogenesis. Mayer JL, Klumpers L, Maslam S, de Kloet ER, Joels M, Lucassen PJ J NEUROENDOCRINOL 2006 18 8 629-631
44. 791996 Mifepristone (RU 486): Current knowledge and future prospects. Goldberg JR, Plescia MG, Anastasio GD ARCH FAM MED 1998 7 3 219-222
45. 792002 The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. Heikinheimo O, Kekkonen R, Lahteenmaki P CONTRACEPTION 2003 68 6 421-426
46. 792922 Psychotic depression and mortality. Vythilingam M, Chen J, Douglas Bremner JD, Mazure CM, Maciejewski PK, Nelson JC AM J PSYCHIATRY 2003 160 3 574-576
47. 792926 New approaches to managing psychotic depression. Schatzberg AF J CLIN PSYCHIATRY 2003 64 Suppl 1 19-23
48. 792929 Psychotic major depression: A benefit-risk assessment of treatment options. Tyrka AR, Price LH, Mello MF, Mello AF, Carpenter LL DRUG SAF 2006 29 6 491-508
49. 792945 Amoxapine: Neuroleptic as well as antidepressant? Cohen BM, Harris PQ, Altesman RI, Cole JO AM J PSYCHIATRY 1982 139 9 1165-1167
50. 792948 Characterization of 24-h cortisol release in obese and non-obese hyperandrogenic women. Miller JE, Bray MA, Faiman C, Reyes FI GYNECOL ENDOCRINOL 1994 8 4 247-254
51. 792952 Ketoconazole administration in hypercortisolemic depression. Wolkowitz OM, Reus VI, Manfredi F, Ingbar J, Brizendine L, Weingartner H AM J PSYCHIATRY 1993 150 5 810-812
52. 792955 Treatment of major depression with steroid suppressive drugs. Murphy BE J STEROID BIOCHEM MOL BIOL 1991 39 2 239-244
53. 792966 Subjective memory complaints: A review of patient self-assessment of memory after electroconvulsive therapy. Prudic J, Peyser S, Sackeim HA J ECT 2000 16 2 121-132
54. 792976 Glucocorticoids: Exemplars of multi-tasking. Buckingham JC BR J PHARMACOL 2006 147 Suppl 1 S258-S268
55. 792996 Regio and stereospecific synthesis of 11 β-substituted 19-norsteroids. Influence of 11β-substitution on progesterone receptor affinity - (1). Belanger A, Philibert D, Teutsch G STEROIDS 1981 37 4 361-382
56. 793000 Mifepristone: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Brogden RN, Goa KL, Faulds D DRUGS 1993 45 3 384-409
57. 793004 Delusional depression: Phenomenology and response to treatment. A prospective study. Lykouras E, Malliaras D, Christodoulou GN, Papakostas Y, Voulgari A, Tzonou A, Stefanis C ACTA PSYCHIATR SCAND 1986 73 3 324-329
58. 793008 Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness. Schatzberg AF, Posener JA, DeBattista C, Kalehzan BM, Rothschild AJ, Shear PK AM J PSYCHIATRY 2000 157 7 1095-1100
59. 793009 Psychotic depression: Advances in conceptualization and treatment. Dubovsky SL, Thomas M HOSP COMMUNITY PSYCHIATRY 1992 43 12 1189-1198
60. 795057 AANA Journal course: Update for nurse anesthetists-anesthetic management during electroconvulsive therapy: Effects on seizure duration and antidepressant efficacy. Hick EM, Black JL AANA J 1999 67 1 87-92
61. 795062 Clinical effects of cortisol synthesis inhibition on treatment-resistant depression. Iizuka H, Kishimoto A, Nakamura J, Mizukawa R JPN J PSYCHOPHARMACOL 1996 16 1 33-36
62. 795070 New directions in the development of antidepressants: The interface of neurobiology and psychiatry. Nemeroff CB HUM PSYCHOPHARMACOL 2002 17 S1 S13-S16
63. 798313 Evaluation of newer treatment interventions for psychotic depression. O'Neal BL, Smith CL, Trivedi M CURR PSYCHIATRY REP 2000 2 4 305-309
64. 798315 Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. Newcomer JW CNS DRUGS 2005 19 Suppl 1 1-93
65. 798320 Prevalence of the metabolic syndrome among patients receiving clozapine. Lamberti JS, Olson D, Crilly JF, Olivares T, Williams GC, Tu X, Tang W, Wiener K, Dvorin S, Dietz MB AM J PSYCHIATRY 2006 163 7 1273-1276
66. 798322 Electroconvulsive therapy of depressive disorders. Folkerts H THER UMSCH 2000 57 2 90-94
67. 798326 Pharmacological properties of mifepristone: Toxicology and safety in animal and human studies. Sitruk-Ware R, Spitz IM CONTRACEPTION 2003 68 6 409-420
68. 799191 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). American Psychiatric Association, Washington, DC, USA DIAGN STATISTICAL MANUAL MENTAL DISORD 2000 414